1
|
Uribe A, Mateus HE, Prieto JC, Palacios MF, Ospina SY, Pasqualim G, da Silveira Matte U, Giugliani R. Identification of mutations in Colombian patients affected with Fabry disease. Gene 2015; 574:325-9. [PMID: 26297554 DOI: 10.1016/j.gene.2015.08.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 08/05/2015] [Accepted: 08/10/2015] [Indexed: 12/22/2022]
Abstract
Fabry Disease (FD) is an X-linked inborn error of glycosphingolipid catabolism, caused by a deficiency of the lisosomal α-galactosidase A (AGAL). The disorder leads to a vascular disease secondary to the involvement of kidney, heart and the central nervous system. The mutation analysis is a valuable tool for diagnosis and genetic counseling. Although more than 600 mutations have been identified, most mutations are private. Our objective was to describe the analysis of nine Colombian patients with Fabry disease by automated sequencing of the seven exons of the GLA gene. Two novel mutations were identified in two patients affected with the classical subtype of FD, in addition to other 6 mutations previously reported. The present study confirms the heterogeneity of mutations in Fabry disease and the importance of molecular analysis for genetic counseling, female heterozygotes detection as well as therapeutic decisions.
Collapse
Affiliation(s)
- Alfredo Uribe
- Centro de Investigaciones en Bioquímica (CIBI), Departamento de Ciencias Biológicas, Universidad de Los Andes, Carrera 1 No. 18° - 12, Bogotá, Colombia.
| | - Heidi Eliana Mateus
- Unidad de Genética, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24N° 63C-69, Bogotá, Colombia.
| | - Juan Carlos Prieto
- Instituto de Genética, Facultad de Medicina, Universidad Javeriana, Carrera 7 No. 40-62 Ed. 32, Bogotá, Colombia
| | - Maria Fernanda Palacios
- Instituto de Genética, Facultad de Medicina, Universidad Javeriana, Carrera 7 No. 40-62 Ed. 32, Bogotá, Colombia
| | - Sandra Yaneth Ospina
- Unidad de Genética, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24N° 63C-69, Bogotá, Colombia
| | - Gabriela Pasqualim
- Centro de Terapia Gênica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-003, Brazil
| | - Ursula da Silveira Matte
- Centro de Terapia Gênica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-003, Brazil; Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-003, Brazil
| | - Roberto Giugliani
- Centro de Terapia Gênica, Centro de Pesquisa Experimental, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-003, Brazil; Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035-003, Brazil
| |
Collapse
|
2
|
Ebrahim HY, Baker RJ, Mehta AB, Hughes DA. Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T). J Inherit Metab Dis 2012; 35:325-34. [PMID: 21972175 DOI: 10.1007/s10545-011-9395-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2011] [Revised: 09/05/2011] [Accepted: 09/08/2011] [Indexed: 11/30/2022]
Abstract
The functional significance of missense mutations in genes encoding acid glycosidases of lysosomal storage disorders (LSDs) is not always clear. Here we describe a method of investigating functional properties of variant enzymes in vitro using a human embryonic kidney epithelial cell line. Site-directed mutagenesis was performed on the parental plasmids containing cDNA encoding for alpha-galactosidase A (α-Gal A) and acid maltase (α-Glu) to prepare plasmids encoding relevant point mutations. Mutant plasmids were transfected into HEK 293 T cells, and transient over-expression of variant enzymes was measured after 3 days. We have illustrated the method by examining enzymatic activities of four unknown α-Gal A and one α-Glu variants identified in our patients with Anderson-Fabry disease and Pompe diseases respectively. Comparison with control variants known to be either pathogenic or non-pathogenic together with over-expression of wild-type enzyme allowed determination of the pathogenicity of the mutation. One leader sequence novel variant of α-Gal A (p.A15T) was shown not to significantly reduce enzyme activity, whereas three other novel α-Gal A variants (p.D93Y, p.L372P and p.T410I) were shown to be pathogenic as they resulted in significant reduction of enzyme activity. A novel α-Glu variant (p.L72R) was shown to be pathogenic as this significantly reduced enzyme activity. Certain acid glycosidase variants that have been described in association with late-onset LSDs and which are known to have variable residual plasma and leukocyte enzyme activity in patients appear to show intermediate to low enzyme activity (p.N215S and p.Q279E α-Gal A respectively) in the over-expression system.
Collapse
Affiliation(s)
- Hatim Y Ebrahim
- Department of Haematology, Royal Free Campus, University College London Medical School, Rowland Hill Street, London, NW3 2PF, UK
| | | | | | | |
Collapse
|
3
|
Sirrs S, Clarke JTR, Bichet DG, Casey R, Lemoine K, Flowerdew G, Sinasac DS, West ML. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Mol Genet Metab 2010; 99:367-73. [PMID: 20022777 DOI: 10.1016/j.ymgme.2009.11.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Revised: 11/10/2009] [Accepted: 11/10/2009] [Indexed: 01/06/2023]
Abstract
The Canadian Fabry Disease Initiative [CFDI] is a longitudinal study evaluating all Canadians diagnosed with Fabry disease [FD]. The study has 3 cohorts: Cohort 1A which includes 81 subjects who were on enzyme replacement therapy [ERT] prior to October 2006, Cohort 1B which has ongoing enrolment of subjects newly started on ERT who are randomized to agalsidase alfa or agalsidase beta, and Cohort 1C where subjects who do not meet nationally accepted Canadian criteria for ERT are followed to assess the natural history of disease complications. The study currently enrols 244 patients [95 males and 149 females] with a mean age of 41.9+/-14.5years. There is a high prevalence of the c.427G>C mutation. Cohort 1A contains 82 patients [59 males, 23 females] of whom 42% are known to have cardiac complications of FD and 38% renal complications. Cohort 1B at the time of writing contained 37 patients [15 males, 22 females] of whom the indications for ERT were cardiac in 55% and renal in 60%. Cohort 1C at the time of writing contained 125 patients [22 males, 103 females]. Enrolment is ongoing in both Cohorts 1B and 1C. When compared to subjects in the Fabry Outcome Survey and the Fabry Registry, subjects in the CFDI are less likely to be male reflecting less ascertainment bias. The CFDI is a robust national data set that will contribute to available data on the natural history of FD and on the comparative efficacy of the two commercially available ERT products.
Collapse
Affiliation(s)
- S Sirrs
- Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Lai LW, Whitehair O, Wu MJ, O'Meara M, Lien YHH. Analysis of splice-site mutations of the alpha-galactosidase A gene in Fabry disease. Clin Genet 2003; 63:476-82. [PMID: 12786754 DOI: 10.1034/j.1399-0004.2003.00077.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Fabry disease is an X-linked disease caused by a defective lysosomal enzyme, alpha-galactosidase A, and characterized by skin lesions and multiorgan involvement, including kidney, heart, and the central nervous system. Currently more than 200 genotypes have been identified, including several aberrant splicing. However, most of the mutation analyses were performed using genomic sequencing only, and therefore some of the splicing mutations were misclassified as missense mutations. In order to predict the splicing event caused by each mutation, we conducted a literature search for all published mutations located near the splice sites, including exonic point mutations, and performed a splice-site score (SSS) analysis. The literature search identified 13 donor-site mutations, including four exonic mutations (S65T, D183S, K213N, and M267I), located at the end of exons 1, 3, 4, and 5, respectively, six acceptor-site mutations, and one new exon creation. All mutated splice sites, except for the one associated with the new exon creation, had a lower SSS than their respective natural sites. Cryptic or newly created sites were identified with SSS from 0.09 to 1.0. The predictions, based on SSS analysis, are in agreement with all six mutations with known cDNA sequence from the literature, including five mutations with exon skipping and one mutation with creation of a new acceptor site. For the S65T genotype, we performed reverse transcription-polymerase chain reaction (RT-PCR) analysis using RNA isolated from the whole-blood sample. We verified that a weak cryptic site (SSS = 0.09) 14 nucleotides downstream was activated and resulted in an insertion of 14 bp and a frameshift stop at codon 106. This change is more consistent with the clinical presentation of the patient, the classical Fabry disease, than the amino acid substitution (S65T), which does not affect the enzyme function. In conclusion, the SSS analysis is very useful for predicting splicing events and genotype/phenotype correlation in Fabry disease. As different mechanisms may be involved in pre-mRNA splicing, it is important to obtain cDNA sequencing for molecular diagnosis.
Collapse
Affiliation(s)
- L-W Lai
- Department of Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA
| | | | | | | | | |
Collapse
|
5
|
Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002; 70:994-1002. [PMID: 11828341 PMCID: PMC379133 DOI: 10.1086/339431] [Citation(s) in RCA: 120] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2001] [Accepted: 01/02/2002] [Indexed: 11/03/2022] Open
Abstract
Fabry disease is an inborn error of glycosphingolipid catabolism, resulting from deficient activity of lysosomal alpha-galactosidase A (alpha-Gal A). A rare alternative splicing that introduces a 57-nucleotide (nt) intronic sequence to the alpha-Gal A transcript from intron 4 of the gene has been identified. In addition, a novel midintronic base substitution that results in substantially increased alternative splicing has been identified in a patient with Fabry disease who has the cardiac variant phenotype. The sequence of the patient's intron 4 contains a single G-->A transversion at genomic nt 9331 (IVS4+919 G-->A ), located at the minus sign4 position of the 3' end of the intronic insertion (nts 9278--9334 in the genomic sequence). Minigene constructs containing the entire intron 4 sequence with G, A, C, or T at nt 9331 within an alpha-Gal A complementary DNA expression vector were prepared and expressed in COS-1 cells. Whereas transfection of the G or T minigenes transcribed predominantly normal-sized transcripts, the transfection of the A or C minigenes produced a large amount of the alternatively spliced transcript. These results suggest that the G-->A mutation, within an A/C-rich domain, results in increased recognition of the alternative splicing by an A/C-rich enhancer-type exonic splicing enhancer. The intronic mutation was not observed in 100 unrelated unaffected men but was present in 6 unrelated patients with cardiac Fabry disease. Reverse-transcriptase polymerase chain reaction of total RNA of various normal human tissues revealed that the alternatively spliced transcript was present in all of the samples, and especially at a higher ratio in the lung and muscle. The normal transcript was present in the patients' lymphoblasts and resulted in approximately 10% residual enzyme activity, leading to a cardiac phenotype of Fabry disease.
Collapse
Affiliation(s)
- Satoshi Ishii
- Department of Human Genetics, Mount Sinai School of Medicine, New York, NY; Usuki Bio Research Center, Oita, Japan; Kagoshima Prefectural Kanoya Hospital, Kagoshima, Japan; and The Tokyo Metropolitan Institute of Medical Science, Tokyo
| | - Shoichiro Nakao
- Department of Human Genetics, Mount Sinai School of Medicine, New York, NY; Usuki Bio Research Center, Oita, Japan; Kagoshima Prefectural Kanoya Hospital, Kagoshima, Japan; and The Tokyo Metropolitan Institute of Medical Science, Tokyo
| | - Reiko Minamikawa-Tachino
- Department of Human Genetics, Mount Sinai School of Medicine, New York, NY; Usuki Bio Research Center, Oita, Japan; Kagoshima Prefectural Kanoya Hospital, Kagoshima, Japan; and The Tokyo Metropolitan Institute of Medical Science, Tokyo
| | - Robert J. Desnick
- Department of Human Genetics, Mount Sinai School of Medicine, New York, NY; Usuki Bio Research Center, Oita, Japan; Kagoshima Prefectural Kanoya Hospital, Kagoshima, Japan; and The Tokyo Metropolitan Institute of Medical Science, Tokyo
| | - Jian-Qiang Fan
- Department of Human Genetics, Mount Sinai School of Medicine, New York, NY; Usuki Bio Research Center, Oita, Japan; Kagoshima Prefectural Kanoya Hospital, Kagoshima, Japan; and The Tokyo Metropolitan Institute of Medical Science, Tokyo
| |
Collapse
|
6
|
Matsumura T, Osaka H, Sugiyama N, Kawanishi C, Maruyama Y, Suzuki K, Onishi H, Yamada Y, Morita M, Aoki M, Kosaka K. Novel acceptor splice site mutation in the invariant AG of intron 6 of α-galactosidase A gene, causing Fabry disease. Hum Mutat 1998. [DOI: 10.1002/(sici)1098-1004(1998)11:6<483::aid-humu18>3.0.co;2-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|